Plasma-Based microRNA Expression Analysis in Advanced Stage NSCLC Patients Treated with Nivolumab

SIMPLE SUMMARY: Nivolumab (anti-PD-1 inhibitor) is the first monoclonal antibody approved for the treatment of NSCLC, with research results showing that patients who had received previous lines of therapy had a better response to this treatment and better overall survival. Tissue-level analyses fail...

Descripción completa

Detalles Bibliográficos
Autores principales: Monastirioti, Alexia, Papadaki, Chara, Kalapanida, Despoina, Rounis, Konstantinos, Michaelidou, Kleita, Papadaki, Maria A., Mavroudis, Dimitrios, Agelaki, Sofia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9564103/
https://www.ncbi.nlm.nih.gov/pubmed/36230658
http://dx.doi.org/10.3390/cancers14194739